A New Optimized Version of a Colorectal Cancer-Targeted Immunotoxin Based on a Non-Immunogenic Variant of the Ribotoxin α-Sarcin
Related Experiment Video
Updated: Aug 9, 2025
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
Javier Narbona1, Rubén G Gordo1, Jaime Tomé-Amat2
1Department of Biochemistry and Molecular Biology, Faculty of Chemical Sciences, Complutense University, 28040 Madrid, Spain.
Abstract:
Due to its incidence and mortality, cancer remains one of the main risks to human health and lifespans. In order to overcome this worldwide disease, immunotherapy and the therapeutic use of immunotoxins have arisen as promising approaches. However, the immunogenicity of foreign proteins limits the dose of immunotoxins administered, thereby leading to a decrease in its therapeutic benefit. In this study, we designed two different variants of non-immunogenic immunotoxins (IMTXA33αSDI and IMTXA33furαSDI) based on a deimmunized variant of the ribotoxin α-sarcin. The inclusion of a furin cleavage site in IMTXA33furαSDI would allow a more efficient release of the toxic domain to the cytosol. Both immunotoxins were produced and purified in the yeast Pichia pastoris and later functionally characterized (both in vitro and in vivo), and immunogenicity assays were carried out. The results showed that both immunotoxins were functionally active and less immunogenic than the wild-type immunotoxin. In addition, IMTXA33furαSDI showed a more efficient antitumor effect (both in vitro and in vivo) due to the inclusion of the furin linker. These results constituted a step forward in the optimization of immunotoxins with low immunogenicity and enhanced antitumor activity, which can lead to potential better outcomes in cancer treatment.
Insights
Researchers developed novel, less immunogenic immunotoxins for cancer therapy. One variant, IMTXA33furαSDI, demonstrated superior antitumor activity, offering potential for improved cancer treatment outcomes.
Area of Science:
- Biotechnology
- Immunology
- Oncology
Background:
- Cancer remains a significant global health threat, driving research into novel therapeutic strategies.
- Immunotherapy and immunotoxins show promise but face limitations due to immunogenicity.
- Foreign protein immunogenicity restricts immunotoxin dosage and therapeutic efficacy.
Purpose of the Study:
- To design and evaluate novel, non-immunogenic immunotoxins for enhanced cancer treatment.
- To assess the functional activity, immunogenicity, and antitumor effects of engineered immunotoxins.
- To investigate the impact of a furin cleavage site on immunotoxin efficacy.
Main Methods:
- De-immunization of ribotoxin α-sarcin to create immunotoxin variants (IMTXA33αSDI, IMTXA33furαSDI).
- Production and purification of immunotoxins in *Pichia pastoris* yeast.
- In vitro and in vivo functional characterization, including immunogenicity assays and antitumor efficacy studies.
Main Results:
- Both designed immunotoxins were functionally active and exhibited reduced immunogenicity compared to wild-type.
- IMTXA33furαSDI demonstrated enhanced antitumor effects in vitro and in vivo.
- The inclusion of a furin cleavage site in IMTXA33furαSDI improved toxic domain release and efficacy.
Conclusions:
- Engineered immunotoxins with reduced immunogenicity and enhanced antitumor activity represent a significant advancement.
- IMTXA33furαSDI shows particular promise for improved cancer treatment outcomes.
- These findings pave the way for optimized immunotoxin-based cancer therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy